Assessment and management of antipsychotic-induced adverse events

Canadian Journal of Psychiatry

Volumn 43, Issue 1 SUPPL., 1998, Pages

  Cortese, Leonardo ^a,b   Pourcher Bouchard, Emmanuelle ^c,d   Williams, Richard ^e,f  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f ROYAL JUBILEE HOSPITAL   (Canada)

Author keywords

Adverse events; Antipsychotics; Psychosis; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

AKATHISIA; CHEMICALLY INDUCED DISORDER; CHOLINERGIC NERVE; DRUG EFFECT; DYSKINESIA; DYSTONIA; HUMAN; METHODOLOGY; PSYCHIATRY; PSYCHOSIS; REVIEW;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CHOLINERGIC FIBERS; DYSKINESIA, DRUG-INDUCED; DYSTONIA; HUMANS; PSYCHIATRY; PSYCHOTIC DISORDERS;

EID: 0032150637     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/07067437980430s105     Document Type: Article

References (44)

1. Borison RL. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 1996;94(389 Suppl):5S-11S.
2. Fink EB, Braden W, Quails CB. Predicting pharmacotherapy outcome by subjective response. J Clin Psychiatry 1982;43:272-5.
3. Hoge SK, Applebaum PS, Lawlor T, Beck JC, Litman R. Greer A, and others. A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 1990;47:949-56.
4. Weiden P, Harrigan M. A clinical guide for diagnosing and managing patients with drug-induced dysphagia. Hosp Commun Psychiatry 1986;37:396-8.
5. Gur RE. Left hemisphere dysfunction and left hemisphere overactivation in schizophrenia. J Abnorm Psychol 1978;87:226-78.
6. Reynolds GP. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 1983;305:527-9.
7. Bracha HS. Asymmetric rotational (circling) behaviour, a dopamine-related asymmetry: preliminary findings in unmedicated and never-medicated schizophrenic patients. Biol Psychiatry 1987;22:995-1003.
8. McCarley RW, Faux SF, Shenton M, Le May M, Cane M, Ballinger R, and others. CT abnormalities in schizophrenia. A preliminary study of their correlations with P300/P200 electrophysiological features and positive/negative symptoms. Arch Gen Psychiatry 1989;46:698-708.
9. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Can J Neural Sci 1980;7:233.
10. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington (DC): American Psychiatric Association; 1992.
11. Guy W. ECDU assessment manual for psychopharmacology. Washington (DC): Department of Education and Welfare; 1976.
12. Simpson GM, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;112(Suppl):11S-19S.
13. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
14. Caligiuri M, Lohr JB, Jeste DV. Parkinsonism in antipsychotic-nalve schizophrenic patients. Am J Psychiatry 1993;150:1343-8.
15. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, and others. A Canadian multicentre, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 1993;13:25-40.
16. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201.
17. Casey DE. Side effect profiles of the new antipsychotic agents. J Clin Psychiatry 1996;57(2 Suppl):40S-45S.
18. Goldberg D. Antipsychotics for dementia-related behavioral disturbances in elderly institutionalized patients. Clin Geriatr 1996;4:1-6.
19. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J Clin Psychiatry 1996;57(11 Suppl):
20. Kopala LC, Frederickson D, Good KP, Honer WG. Symptoms in neuroleptic-naïve, first-episode schizophrenia: response to risperidone. Biol Psychiatry 1996;39:296-8.
21. Bezchlibnyk-Butler KZ, Jeffries JL, editors. Clinical handbook of psychotropic drugs. 5th ed. Gottingen, Germany: Hogrefe and Huber Publishers; 1995.
22. Van Kammen DP, Marder SR. Clozapine. In: Kaplan H, Sadock B, editors. Comprehensive Textbook of Psychiatry. 6th ed. Volume 2. Baltimore: Williams & Wilkins; 1995. p 1979-87.
23. Casey DE. Neuroleptic-induced acute extrapyramidal syndrome and tardive dyskinesia. Psychiatric Clin North Amer 1993;16:589-610.
24. Braude WM, Barnes TRE, Gold SM. Clinical characteristics of akathisia: a systematic classification of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-50.
25. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of antipsychotic-induced akathisia. J Clin Psychopharmacol 1990;10:12-21.
26. Kane JM, Woemer M, Kleinhold P. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984;20:387-9.
27. Kane JM, Woemer M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:54-8.
28. Woemer M, Kane JM, Leiberman J. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;1:34-42.
29. Kane JM, Woemer M, Pollock S, Lieberman J. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-32.
30. Marder SR. Risperidone, clinical development: North American results. Clin Neuropharmacol 1997;15:92A-93A.
31. Beasley CM Jr. Tollefson G, Tran P, Satterlee W, Sanger T. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 1996;14:11-23.
32. Thakes GK, Nguyen JA, Strauss ME. Clonazepam treatment of tardive dyskinesia: a practical GABAergic strategy. Am J Psychiatry 1990;147:445-51.
33. Shriqui CL, Annable L. Tadive dyskinesia. In: Shriqui CL, Nasrellah HA, editors. Contemporary issues in the treatment of schizophrenia, Washington (DC): American Psychiatric Press; 1995. p 585-632.
34. Bymaster FP, Hemrick-Lueche SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacol 1996;124:87-94.
35. Bilder RM, Turkel E, Lipshutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 1992;28:353-66.
36. MacPherson R, Double DB, Rowlands RP, Harrison DM. Long-term psychiatric patients' understanding of antipsychotic medication. Hosp Community Psychiatry 1993;44:71-3.
37. Baldesserini RJ. Drugs and the treatment of psychiatric disorders. In: Oilman AG, Ruhl TW, Neis AS, editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergomon; 1990. p 383-414.
38. Wirshing DA, Marder SR, Goldstein D, and others. Novel antipsychotics: comparison of weight gain liabilities. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kamuela, HI.
39. Peuskens T. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
40. Risch SC, Groom GP, Janowski DS. Interfaces of psychopharmacology and cardiology: part 2. J Clin Psychiatry 1981;42:47-59.
41. American Psychiatric Association Task Force Report 27: Sudden death in psychiatric patients: the role of neurolepic drugs. Washington (DC): American Psychiatric Association; 1987.
42. Levinson DF, Simpson GM. Serious non-extrapyramidal adverse effects of neuroleptics: Sudden death, agranulocytosis and hepatotoxicity. In: Meltzer MY, editor. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987. p 1431-6.
43. Caroff S. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
44. Rosenberg MR, Green M. Neuroleptic malignant syndrome: a review of response to therapy. Arch Intern Med 1989;149:1927-31.